PMID: 6971700Mar 15, 1981Paper

Methotrexate: an active drug in bladder cancer

Cancer
R B NataleD W Braun

Abstract

Forty-nine patients with transitional urothelial tract tumors received methotrexate: 0.5-1.0 mg/kg I.V. Q W (40 patients) or 250 mg/M2 in a 2-hour infusion with citrovorum factor rescue 24 hours later (nine patients). Eleven (26%, 95% confidence limits 13-39%) of 42 patients with bidimensionally measurable metastases achieved partial remission. Most responses occurred within 2-3 weeks and persisted for a median duration of six months (range, 2-20). Response rates were increased to 38% (6/16 patients, 95% confidence limits 18-65%) in patients who had no prior chemotherapy, and a 90-100% performance status (50, 5/10 patients, 95% confidence limits 22-78%) compared with 19% (5/26, 95% confidence limits 8-37%) in patients who had prior chemotherapy and a less than or equal to 80% performance status (19%, 6/32 cases, 95% confidence limits 9-32%). Toxicity included mucositis and myelosuppression. A review of the literature coupled with the present data suggest that methotrexate is as active as cisplatin in the treatment of patients with advanced urinary bladder cancer.

References

Jan 1, 1977·British Journal of Urology·A G TurnerH J Bloom
Jun 1, 1976·Plastic and Reconstructive Surgery·M A Mandel
Dec 1, 1971·British Journal of Urology·M Pavone-Macaluso
Aug 1, 1974·British Journal of Urology·R R HallD M Wallace
Oct 1, 1966·The Journal of Urology·A Abbassian, D M Wallace
Aug 1, 1972·The Journal of Urology·C C AltmanM Cardozo
Jun 12, 1967·JAMA : the Journal of the American Medical Association·S Tindel
Nov 1, 1969·Clinical Pharmacology and Therapeutics·D G LieglerV T Oliverio
Apr 1, 1966·The British Journal of Surgery·J I BurnR A Sellwood

❮ Previous
Next ❯

Citations

Sep 1, 1997·Seminars in Surgical Oncology·W M Brinkley, F M Torti
Jan 1, 1992·Cancer Chemotherapy and Pharmacology·R S Miller, F M Torti
May 18, 2004·Cancer Treatment Reviews·John D ChesterAndrew S Protheroe
Apr 1, 1996·Urology·S B Malkowicz, D J Vaughn
Jan 1, 1997·European Journal of Cancer : Official Journal for European Organization for Research and Treatment of Cancer (EORTC) [and] European Association for Cancer Research (EACR)·W M StadlerF A Dorr
Oct 1, 1988·The British Journal of Radiology·M J TomlinsonP J Smith
Oct 31, 2006·Expert Review of Anticancer Therapy·Aude Flechon, Jean-Pierre Droz
Oct 9, 2012·Seminars in Oncology·Joaquim Bellmunt, Daniel P Petrylak
Nov 26, 2011·Cancer Treatment Reviews·Daniel CastellanoJoaquim Bellmunt
Apr 1, 1984·Urology·M S SolowayA Blatnik
Dec 17, 2008·Progrès en urologie : journal de l'Association française d'urologie et de la Société française d'urologie·T Lebret, A Méjean
Feb 1, 1989·European Journal of Cancer & Clinical Oncology·G BlackledgeB Uscinska
Jan 1, 1989·Seminars in Surgical Oncology·Z Wajsman, I W Klimberg
Aug 1, 1983·The Australian and New Zealand Journal of Surgery·L M HarewoodM J Leyden
Jan 1, 1986·Seminars in Surgical Oncology·R V Roemeling, W J Hrushesky
Aug 1, 1985·British Journal of Urology·S B KayeA J Hart
Dec 1, 1987·British Journal of Urology·G W Bowyer, T W Davies
Oct 22, 2005·Clinical Oncology : a Journal of the Royal College of Radiologists·J T Roberts
Aug 1, 1987·Cancer·A Yagoda
Jan 1, 1993·Scandinavian Journal of Urology and Nephrology·E RintalaS Sander
Jun 24, 2006·The Oncologist·Seth M CohenMichael L Grossbard
May 20, 2020·International Journal of Molecular Sciences·Przemysław KoźmińskiEwa Gniazdowska
May 1, 1993·The Journal of Urology·J B Thrasher, E D Crawford
Apr 1, 1985·The Journal of Urology·T AhmedN Geller
Dec 1, 1986·The Journal of Urology·I W Klimberg, Z Wajsman

❮ Previous
Next ❯

Related Concepts

Trending Feeds

COVID-19

Coronaviruses encompass a large family of viruses that cause the common cold as well as more serious diseases, such as the ongoing outbreak of coronavirus disease 2019 (COVID-19; formally known as 2019-nCoV). Coronaviruses can spread from animals to humans; symptoms include fever, cough, shortness of breath, and breathing difficulties; in more severe cases, infection can lead to death. This feed covers recent research on COVID-19.

Blastomycosis

Blastomycosis fungal infections spread through inhaling Blastomyces dermatitidis spores. Discover the latest research on blastomycosis fungal infections here.

Nuclear Pore Complex in ALS/FTD

Alterations in nucleocytoplasmic transport, controlled by the nuclear pore complex, may be involved in the pathomechanism underlying multiple neurodegenerative diseases including Amyotrophic Lateral Sclerosis and Frontotemporal Dementia. Here is the latest research on the nuclear pore complex in ALS and FTD.

Applications of Molecular Barcoding

The concept of molecular barcoding is that each original DNA or RNA molecule is attached to a unique sequence barcode. Sequence reads having different barcodes represent different original molecules, while sequence reads having the same barcode are results of PCR duplication from one original molecule. Discover the latest research on molecular barcoding here.

Chronic Fatigue Syndrome

Chronic fatigue syndrome is a disease characterized by unexplained disabling fatigue; the pathology of which is incompletely understood. Discover the latest research on chronic fatigue syndrome here.

Evolution of Pluripotency

Pluripotency refers to the ability of a cell to develop into three primary germ cell layers of the embryo. This feed focuses on the mechanisms that underlie the evolution of pluripotency. Here is the latest research.

Position Effect Variegation

Position Effect Variagation occurs when a gene is inactivated due to its positioning near heterochromatic regions within a chromosome. Discover the latest research on Position Effect Variagation here.

STING Receptor Agonists

Stimulator of IFN genes (STING) are a group of transmembrane proteins that are involved in the induction of type I interferon that is important in the innate immune response. The stimulation of STING has been an active area of research in the treatment of cancer and infectious diseases. Here is the latest research on STING receptor agonists.

Microbicide

Microbicides are products that can be applied to vaginal or rectal mucosal surfaces with the goal of preventing, or at least significantly reducing, the transmission of sexually transmitted infections. Here is the latest research on microbicides.